Literature DB >> 19393238

Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.

E L Lane1, L Vercammen, M A Cenci, P Brundin.   

Abstract

In some patients, graft-induced dyskinesia develops following intrastriatal transplantation of embryonic neural tissue for the treatment of Parkinson's disease. The mechanisms underlying these involuntary movements need to be clarified before this approach to clinical cell therapy can be developed further. We previously found that rats with 6-OHDA lesions, primed with L-DOPA treatment and that have subsequently undergone intrastriatal graft surgery exhibit involuntary movements when subjected to amphetamine. This model of amphetamine-induced AIMs reflects a pattern of post-graft behaviours that in the absence of robust spontaneous GID in the rat is the closest approximation that we currently have available. We now show that they are associated with the chronic administration of L-DOPA prior to the transplantation surgery. We also demonstrate that neither changes in c-fos nor FosB/DeltaFosB expression in the lateral striatum are associated with the expression of these behaviours. Taken together, these data reveal that the severity of abnormal movements elicited by amphetamine in grafted animals may relate to previous L-DOPA exposure and dyskinesia development, but they develop through mechanisms that are independent of FosB/DeltaFosB upregulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393238     DOI: 10.1016/j.expneurol.2009.04.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  14 in total

1.  Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism.

Authors:  Daniella Rylander; Vincenza Bagetta; Valentina Pendolino; Elisa Zianni; Shane Grealish; Fabrizio Gardoni; Monica Di Luca; Paolo Calabresi; M Angela Cenci; Barbara Picconi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 3.  Potential for cell therapy in Parkinson's disease using genetically programmed human embryonic stem cell-derived neural progenitor cells.

Authors:  Rajesh Ambasudhan; Nima Dolatabadi; Anthony Nutter; Eliezer Masliah; Scott R Mckercher; Stuart A Lipton
Journal:  J Comp Neurol       Date:  2014-05-07       Impact factor: 3.215

4.  Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum.

Authors:  Kathy Steece-Collier; David J Rademacher; Katherine Soderstrom
Journal:  Basal Ganglia       Date:  2012-02-11

Review 5.  Dopamine cell transplantation in Parkinson's disease: challenge and perspective.

Authors:  Yilong Ma; Shichun Peng; Vijay Dhawan; David Eidelberg
Journal:  Br Med Bull       Date:  2011-08-28       Impact factor: 4.291

Review 6.  Cell therapeutics in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 7.  Treatment of Parkinson's disease using cell transplantation.

Authors:  Olle Lindvall
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

8.  Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease.

Authors:  Eunju Shin; Elisabetta Tronci; Manolo Carta
Journal:  Parkinsons Dis       Date:  2012-06-11

9.  Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.

Authors:  Emma L Lane; David J Harrison; Elena Ramos-Varas; Rachel Hills; Sophie Turner; Mariah J Lelos
Journal:  Mov Disord       Date:  2021-11-12       Impact factor: 9.698

Review 10.  Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?

Authors:  Daniella Rylander Ottosson; Emma Lane
Journal:  Front Cell Neurosci       Date:  2016-02-08       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.